Aptevo Therapeutics (APVO) Competitors $4.41 -0.12 (-2.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APVO vs. COEP, CDT, OBSV, CERO, SNGX, NLSP, EVOK, EYEN, ADIL, and GRIShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Coeptis Therapeutics (COEP), Conduit Pharmaceuticals (CDT), ObsEva (OBSV), CERo Therapeutics (CERO), Soligenix (SNGX), NLS Pharmaceutics (NLSP), Evoke Pharma (EVOK), Eyenovia (EYEN), Adial Pharmaceuticals (ADIL), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Coeptis Therapeutics Conduit Pharmaceuticals ObsEva CERo Therapeutics Soligenix NLS Pharmaceutics Evoke Pharma Eyenovia Adial Pharmaceuticals GRI Bio Coeptis Therapeutics (NASDAQ:COEP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Does the media favor COEP or APVO? In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score. Company Overall Sentiment Coeptis Therapeutics Neutral Aptevo Therapeutics Neutral Is COEP or APVO more profitable? Aptevo Therapeutics' return on equity of -353.04% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -1,094.50% -219.97% Aptevo Therapeutics N/A -353.04%-132.42% Which has better valuation and earnings, COEP or APVO? Aptevo Therapeutics has higher revenue and earnings than Coeptis Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$80K72.73-$21.27M-$0.29-0.49Aptevo Therapeutics$3.11M0.72-$17.41MN/AN/A Do insiders and institutionals hold more shares of COEP or APVO? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor COEP or APVO? Aptevo Therapeutics received 194 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Coeptis Therapeutics an outperform vote while only 50.13% of users gave Aptevo Therapeutics an outperform vote. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67%Aptevo TherapeuticsOutperform Votes19950.13% Underperform Votes19849.87% Do analysts recommend COEP or APVO? Aptevo Therapeutics has a consensus target price of $10,952.00, indicating a potential upside of 248,244.67%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aptevo Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, COEP or APVO? Coeptis Therapeutics has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.01, indicating that its stock price is 401% more volatile than the S&P 500. SummaryAptevo Therapeutics beats Coeptis Therapeutics on 9 of the 13 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.25M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales0.72195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book0.005.104.794.78Net Income-$17.41M$151.51M$120.07M$225.60M7 Day Performance7.82%-2.15%-1.90%-1.23%1 Month Performance-98.80%-3.14%11.45%3.37%1 Year Performance-99.96%11.50%30.63%16.58% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.0482 of 5 stars$4.41-2.6%$10,952.00+248,244.7%-100.0%$2.25M$3.11M0.0050Gap UpCOEPCoeptis Therapeutics0.3772 of 5 stars$0.20+11.3%N/A-83.7%$8.14M$80,000.00-0.612Gap UpCDTConduit PharmaceuticalsN/A$0.08-5.0%N/A-98.5%$7.96MN/A0.003OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCEROCERo TherapeuticsN/A$0.05-8.3%N/AN/A$7.82MN/A0.008SNGXSoligenix0.7359 of 5 stars$3.03-4.1%N/A-67.4%$7.61M$840,000.00-0.4220Positive NewsGap UpNLSPNLS Pharmaceutics0.3646 of 5 stars$1.90-0.5%N/A+332.6%$7.25MN/A0.006News CoverageGap UpEVOKEvoke Pharma0.0369 of 5 stars$4.77+1.3%N/A-61.9%$7.11M$5.18M-0.434News CoverageEYENEyenovia1.4897 of 5 stars$0.08-2.9%$2.00+2,366.1%-94.9%$7.01M$31,832.00-0.1140Gap DownHigh Trading VolumeADILAdial Pharmaceuticals3.3523 of 5 stars$1.09flat$8.00+633.9%-38.9%$6.98MN/A0.0020News CoveragePositive NewsGRIGRI Bio2.5236 of 5 stars0.77-3.8%N/A-98.0%$6.88MN/A0.001 Related Companies and Tools Related Companies COEP Alternatives CDT Alternatives OBSV Alternatives CERO Alternatives SNGX Alternatives NLSP Alternatives EVOK Alternatives EYEN Alternatives ADIL Alternatives GRI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APVO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
